Optimistic Buy Rating for Pyxis Oncology Amid Strategic Focus and Promising Drug Developments

Leerink Partners analyst Jeffrey La Rosa has maintained their bullish stance on PYXS stock, giving a Buy rating on March 19.

Jeffrey La Rosa has given his Buy rating due to a combination of factors surrounding Pyxis Oncology’s strategic focus and promising developments. The company is concentrating its efforts on advancing micvotabart pelidotin, a targeted antibody drug conjugate, through its Phase 1 trial for squamous cell carcinoma of the head and neck. This focused approach, including modest workforce reductions and the CEO taking on additional responsibilities, is aimed at maximizing clinical investments and potential returns.
La Rosa acknowledges the current undervaluation of Pyxis Oncology, with its market capitalization significantly lower than its cash position. Despite some investor skepticism, he is optimistic about the drug’s unique mechanism and early efficacy signals, which could reduce risks in ongoing trials. The company’s recent financial updates and strategic decisions further reinforce this positive outlook, supporting the Buy rating.

PYXS’s price has also changed dramatically for the past six months – from $3.660 to $1.060, which is a -71.04% drop .